<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703976</url>
  </required_header>
  <id_info>
    <org_study_id>07-021</org_study_id>
    <nct_id>NCT00703976</nct_id>
  </id_info>
  <brief_title>Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase II Randomized Trial of Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects (good and bad) of chemoradiotherapy with
      or without Bevacizumab (Avastin). Chemoradiotherapy is the combination of chemotherapy (the
      drugs pemetrexed and cetuximab) and radiation. Pemetrexed is not approved by the Food and
      Drug Administration (FDA) for head and neck cancer when used in combination with radiation
      therapy. Cetuximab is also approved by the FDA for head and neck cancers in patients who have
      failed other chemotherapy treatments. Bevacizumab is approved by the Food and Drug
      Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of
      chemotherapy. In this study, the use of bevacizumab is investigational.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Patients with squamous cell carcinoma of the head and neck (HNSCC) are increasingly treated
      with primary chemoradiotherapy. The incorporation of novel targeted therapies to
      chemoradiotherapy is of major interest since it may potentially improve efficacy without
      significantly increasing toxicity. Radiation and cetuximab, a chimeric anti-epidermal growth
      factor receptor monoclonal antibody, has emerged as a standard non-surgical therapy for stage
      III/IV HNSCC. Bevacizumab, an anti-vascular endothelial growth factor antibody is currently
      being investigated in HNSCC with promising results. A phase II study investigating the
      combination of pemetrexed and bevacizumab in recurrent or metastatic HNSCC is currently
      ongoing at our institution with encouraging results (UPCI# 05-002). In addition, we are
      completing a phase I trial of radiation, cetuximab plus pemetrexed (UPCI #05-005). Pemetrexed
      was dose escalated in successive cohorts of patients on 3 dose levels: starting dose level
      (0) 350 mg/m2, dose level (-1) 200 mg/m2, dose level (+1) 500 mg/m2. Currently three patients
      have been treated at dose level +1 (pemetrexed 500 mg/m2) which will be the pemetrexed dose
      in this study. No dose limiting toxicities (DLTs) have been observed at this dose level,
      which was the maximum tolerated dose (MTD) for the combination regimen in previously
      non-irradiated patients.

      Specific aims

      To evaluate the progression-free survival at 2 years (primary endpoint), locoregional and
      distant disease-free survival, overall survival, toxicities and quality of life with the
      combination of radiation, cetuximab and pemetrexed with or without bevacizumab in patients
      with locally advanced HNSCC. Also, we plan to collect tumor tissue from previous diagnostic
      procedures and baseline blood specimens for future correlative studies.

      Subject population

      We will enroll patients with previously untreated stage III/IV squamous cell carcinoma or
      undifferentiated carcinoma of the head and neck (except nasopharynx and unknown primary).
      Patients should not have active bleeding due to HNSCC or history of persistent bleeding due
      to HNSCC that required major intervention (surgery or embolization) to be controlled. Please
      see section 3 for detailed eligibility criteria.

      Treatment plan

      Patients will be randomized in two arms. In arm A, patients will be treated with radiation
      2Gy/day for 7 weeks to a total of 70 Gy, cetuximab 250mg/m2 weekly during radiation, after a
      loading dose of 400mg/m2 one week prior starting radiation, and pemetrexed 500mg/m2 every 21
      days for 3 cycles. In arm B, patients will be treated with the same regimen with the addition
      of bevacizumab 15mg/kg every 21 days for 3 cycles (see section 5 for detailed treatment plan
      and dose modifications).

      Statistical design and sample size

      Phase II, randomized, multi-center study with progression-free survival at 2 years as the
      primary endpoint. The historical control is a 2-year progression-free survival of 46% with
      radiation plus cetuximab alone. We assume a 2 year progression free survival of 64% (40%
      relative improvement in progression-free survival over historical control) as worthy of
      further testing. We will require 40 evaluable patients per arm for a total of 80 patients.
      Alpha = 0.1, beta = 0.1; all tests one-tailed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year Progression-free Survival (PFS)</measure>
    <time_frame>18 months to patient accrual and 2 years of follow-up after closing accrual.</time_frame>
    <description>Two-year PFS is an estimated percentage of participants without disease progression (locoregional or distant) at two years after the start of study treatment. Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as: at least a 20% (and at least 5 millimeters) increase in the sum of the diameters of target lesions, or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year Overall Survival (OS)</measure>
    <time_frame>2 years of follow-up after closing accrual</time_frame>
    <description>Two-year OS is an estimated percentage of participants still living at two years after the start of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab, Pemetrexed and Radiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
    <arm_group_label>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.</description>
    <arm_group_label>Cetuximab, Pemetrexed and Radiation therapy</arm_group_label>
    <arm_group_label>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.</description>
    <arm_group_label>Cetuximab, Pemetrexed and Radiation therapy</arm_group_label>
    <arm_group_label>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
    <arm_group_label>Cetuximab, Pemetrexed and Radiation therapy</arm_group_label>
    <arm_group_label>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have pathologically confirmed AJCC 6th edition (see Appendix) stage
             III or IV (M0) squamous cell carcinoma or undifferentiated or poorly differentiated
             carcinoma of the oropharynx, larynx, or hypopharynx with no evidence of distant
             metastasis. Biopsy sampling of primary tumor with pathology report documentation of
             confirmed diagnostic tissue type is required. Patients should be evaluated by a
             Radiation Oncologist, Medical Oncologist and Otolaryngologist prior to enrolling on
             study.

          -  No prior treatment for head and neck cancer. Limited, organ-preserving surgery is
             allowed

          -  ECOG performance status 0-1

          -  Unidimensionally measurable disease is not required. However, patients should require
             treatment with full dose radiotherapy (not postoperative)

          -  Age greater or equal to 18 years

          -  Absolute neutrophil count greater or equal to 1500/µl, Platelet count greater or equal
             to 100,000/µl

          -  Creatinine clearance 45 ml/min or higher calculated using the Cockcroft-Gault formula

          -  Total bilirubin within normal limits and AST/ALT less than 3 times the upper limit of
             normal

          -  Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC)
             ratio. For UPC ratio &gt;0.5, 24-hour urine protein should be obtained and the level must
             be &lt;1000mg for patients to be eligible

          -  Informed consent must be obtained from all patients prior to beginning therapy.
             Patients should have the ability to understand and the willingness to sign a written
             informed consent document

          -  Patients should be willing and able to take folic acid and vitamin B12 supplementation
             and should interrupt aspirin or other non-steroidal anti-inflammatory agents for a
             5-day period

          -  The use of anti-platelet agents(e.g. dipyridamole (Persatine), ticlopidine (Ticlid),
             clopidogrel (Plavix)) is allowed only if patient is not receiving aspirin or NSAID's
             known to inhibit platelet function.

          -  Patients who meet the following criteria will be excluded due to the possibility of
             increased risk for tumor bleeding with bevacizumab therapy:

               -  active bleeding due to head and neck cancer of more than ½ teaspoon of bright red
                  blood per episode or history of persistent bleeding due to SCCHN that required
                  major intervention (surgery or embolization) to be controlled.

               -  history of gross hemoptysis (bright red blood of .05 teaspoon or more per episode
                  of coughing) less than or equal to 3 months prior to enrollment

               -  history of coagulopathy or hemorrhagic disorders

          -  Patients should not be on therapeutic anticoagulation (prophylactic use of warfarin 1
             mg per day is allowed) and INR should be &lt; 1.5 at registration.

          -  Patients with a prior history of squamous cell or basal carcinoma of the skin or in
             situ cervical cancer must have been curatively treated. Patients with a history of
             other prior malignancy must have been treated with curative intent and must have
             remained disease-free for 5 years post diagnosis

          -  Patients with history of hypertension must be well-controlled upon study entry
             (≤150/90) on a stable regimen of anti-hypertensive therapy. Patients should not have
             any prior history of hypertensive crisis or hypertensive encephalopathy.

          -  No major surgical procedure, open biopsy, or significant traumatic injury within 28
             days prior to study enrollment, or anticipation of need for major surgical procedure
             during the course of the study. Prior surgical therapy will consist only of incisional
             or excisional biopsy and organ sparing procedures such as debulking of airway
             compromising tumors or neck dissection in a patient with an existing primary tumor.
             Any non-biopsy procedure must have taken place &gt;4 weeks but &lt;3 months of initiating
             protocol treatment. No history of abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess within 6 months prior to registration. No serious non-healing
             wound, ulcer, or bone fracture.

          -  No unstable angina or myocardial infarction within the previous 6 months; no
             symptomatic congestive heart failure; no serious cardiac arrhythmia requiring
             medication; no clinically significant peripheral vascular disease; no history of
             aortic dissection; no history of any CNS cerebrovascular ischemia or stroke within the
             last 6 months; no active serious infection. All patients will have a baseline EKG. If
             abnormalities consistent with active coronary artery disease are detected, the patient
             will be referred to a cardiologist for appropriate evaluation and management prior to
             treatment on study

          -  For patients who have baseline clinically significant pleural or peritoneal effusions
             (on the basis of symptoms or clinical examination) before initiation of protocol
             therapy, consideration should be given to draining the effusion prior to starting
             therapy due the potential of increased toxicity with pemetrexed in that setting

          -  Submission of archival tumor samples, unstained slides or blocks, for correlative
             studies is strongly encouraged, but not required for subject participation if tissue
             is not readily available or quantity is not sufficient for release per submitting
             pathologist.

        Exclusion Criteria:

          -  Patients who are receiving any other investigational agents.

          -  Ineligible will be patients with uncontrolled intercurrent illness including, but not
             limited to,ongoing or active infection or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Patients should not have prior history of a serious reaction to a monoclonal antibody.
             Patients with known hypersensitivity to Chinese hamster ovary cell products or other
             recombinant human antibodies are not eligible.

          -  Women must not be pregnant or breast feeding because chemotherapy may be harmful to
             the fetus or the nursing infant. Pregnant women are excluded from this study because
             chemotherapy and/or bevacizumab have the potential for teratogenic or abortifacient
             effects.

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study because of possible drug interactions with study drugs. Appropriate studies
             will be undertaken in patients receiving combination anti-retroviral therapy when
             indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Bauman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 80 patients were enrolled, only 78 began the study because 2 were found to be ineligible prior to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab, Pemetrexed and Radiation Therapy</title>
          <description>Cetuximab, Pemetrexed and Radiation therapy
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
        </group>
        <group group_id="P2">
          <title>Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab</title>
          <description>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab, Pemetrexed and Radiation Therapy</title>
          <description>Cetuximab, Pemetrexed and Radiation therapy
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
        </group>
        <group group_id="B2">
          <title>Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab</title>
          <description>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="39" upper_limit="69"/>
                    <measurement group_id="B2" value="56" lower_limit="35" upper_limit="76"/>
                    <measurement group_id="B3" value="56" lower_limit="35" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2-year Progression-free Survival (PFS)</title>
        <description>Two-year PFS is an estimated percentage of participants without disease progression (locoregional or distant) at two years after the start of study treatment. Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as: at least a 20% (and at least 5 millimeters) increase in the sum of the diameters of target lesions, or the appearance of one or more new lesions.</description>
        <time_frame>18 months to patient accrual and 2 years of follow-up after closing accrual.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Pemetrexed and Radiation Therapy</title>
            <description>Cetuximab, Pemetrexed and Radiation therapy
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab</title>
            <description>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Progression-free Survival (PFS)</title>
          <description>Two-year PFS is an estimated percentage of participants without disease progression (locoregional or distant) at two years after the start of study treatment. Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as: at least a 20% (and at least 5 millimeters) increase in the sum of the diameters of target lesions, or the appearance of one or more new lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69" upper_limit="92"/>
                    <measurement group_id="O2" value="75" lower_limit="64" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Overall Survival (OS)</title>
        <description>Two-year OS is an estimated percentage of participants still living at two years after the start of study treatment.</description>
        <time_frame>2 years of follow-up after closing accrual</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants (Overall Study)</title>
          </group>
          <group group_id="O2">
            <title>Cetuximab, Pemetrexed and Radiation Therapy</title>
            <description>Cetuximab, Pemetrexed and Radiation therapy
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab, Pemetrexed, Radiation Therapy Plus Bevacizumab</title>
            <description>Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab
Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Overall Survival (OS)</title>
          <description>Two-year OS is an estimated percentage of participants still living at two years after the start of study treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81" upper_limit="96"/>
                    <measurement group_id="O2" value="91" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O3" value="87" lower_limit="77" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected/monitored &quot;per Arm/Group&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants (Overall Study)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin without documented infection)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leak (including anastomotic), GI, Leak NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L), Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Meninges (meningitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation, Chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Coagulation - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia (fever of unknown origin without documented infection)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Otitis, external ear (non-infectious)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, External ear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thyroid function, high (hyperthyroidism, thyrotoxicosis)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vision-photophobia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dental: dentures or prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Salivary gland changes/saliva</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Dental/teeth/peridontal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Face</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L), Neck NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Neck NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Oral cavity-gums (gingivitis)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Upper aerodigestive NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Foreign body (e.g., graft, implant, prosthesis, stent)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Neck NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haptoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cervical spine-range of motion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fibrosis-deep connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), Extremity-upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy), Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis, Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Trismus (difficulty, restriction or pain when opening mouth)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Neck</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain, Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mood alteration, Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mood alteration, Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU, Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sexual/Reproductive Function - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Nose</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, Respiratory tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Larynx</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hiccoughs (hiccups, singultus)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation, Chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation, Radiation</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain, Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Phlebitis (including superficial thrombosis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Bauman, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-623-7833</phone>
      <email>baumanje@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

